Table 4: Results of the enzyme-linked immunosorbent assay (ELISA) for levels of inflammatory markers tumor necrosis factor-alpha (TNF-α) and IL-1β. during the treatment period (before the first treatment, and before treatments 2 – 4), and on selected days during the 90-day follow-up period.
| Group | Treatments | Post-Tx follow up in days | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 1 | 7 | 15 | 30 | 60 | 90 | |
| TNF-α | ||||||||||
| G - Avg | 98.664 | 95.416 | 99.747 | 136.637 | 159.017 | 187.460 | 216.554 | 174.610 | 208.901 | 155.118 |
| G1 - SD | 1.327 | 23.482 | 1.021 | 1.123 | 4.390 | 0.715 | 10.005 | 6.432 | 1.634 | 1.940 |
| G2 - Avg | 177.209 | 171.578 | 148.549 | 117.867 | 128.552 | 283.908 | 135.843 | 147.033 | 186.305 | 174.899 |
| G2 - SD | 24.809 | 3.573 | 11.639 | 2.552 | 16.233 | 14.804 | 0.204 | 8.882 | 15.212 | 0.715 |
| IL-1β | ||||||||||
| G1 - Avg | 300.7 | 320.8 | 334.6 | 277.3 | 323.9 | 546.5 | 340.8 | 377.4 | 406.6 | 358.7 |
| G1 - SD | 2.2 | 29.0 | 5.4 | 10.4 | 4.6 | 2.1 | 19.1 | 4.1 | 13.9 | 19.7 |
| G2 - Avg | 348.4 | 351.9 | 374.1 | 285.5 | 303.6 | 470.7 | 350.7 | 305.5 | 328.1 | 267.1 |
| G2 - SD | 4.1 | 4.1 | 14.5 | 8.7 | 16.5 | 4.8 | 11.0 | 3.1 | 6.5 | 4.9 |